Glucuronidation is a listed clearance mechanism for 1 in 10 of the top 200 prescribed drugs. The objective of this article is to encourage those studying ligand interactions with UDP-glucuronosyltransferases (UGTs) to adequately consider the potential consequences of in vitro UGT inhibition in humans. Spurred on by interest in developing potent and selective inhibitors for improved confidence around UGT reaction phenotyping, and the increased availability of recombinant forms of human UGTs, several recent studies have reported in vitro inhibition of UGT enzymes. In some cases, the observed potency of UGT inhibitors in vitro has been interpreted as having potential relevance in humans via pharmacokinetic drug-drug interactions. Although there are reported examples of clinically relevant drug-drug interactions for UGT substrates, exposure increases of the aglycone are rarely greater than 100% in the presence of an inhibitor relative to its absence (i.e., AUC i /AUC <2). This small magnitude in change is in contrast to drugs primarily cleared by cytochrome P450 enzymes, where exposures have been reported to increase as much as 35-fold on coadministration with an inhibitor (e.g., ketoconazole inhibition of CYP3A4-catalyzed terfenadine metabolism). In this article the evidence for purported clinical relevance of potent in vitro inhibition of UGT enzymes will be assessed, taking the following into account: in vitro data on the enzymology of glucuronide formation from aglycone, pharmacokinetic principles based on empirical data for inhibition of metabolism, and clinical data on the pharmacokinetic drug-drug interactions of drugs primarily cleared by glucuronidation.
In considering the clinical relevance of pharmacokinetic drug-drug interactions mediated by drug-metabolizing enzymes, efficacy linked to dosage requirements and/or toxicity can be considered as appropriate endpoints. The conduct of these studies in early drug discovery and for definitive purposes (Bjornsson et al., 2003) has been previously described. For metabolized drugs primarily cleared by cytochrome P450 (P450) substrates, numerous examples exist of clinically relevant pharmacokinetic drug-drug interactions. Ketoconazole inhibition of CYP3A-catalyzed terfenadine metabolism, leading to as much as a 35-fold increase in drug exposure [area under the curve (AUC)] is a well known example (Boxenbaum, 1999) . The clinical consequences were cardiac arrhythmias, torsades de pointes, and even death in some cases (Monaghan et al., 1990) . Also, for CYP3A substrates, clinically relevant inhibition interactions with foodstuffs such as grapefruit juice, containing complex mixtures of flavonoids and furanocoumarins, have been described (Goosen et al., 2004a,b) . However, as will be discussed in this article, the observation of potent flavonoid inhibition of UGT enzymes in vitro is not correlated with clinically relevant interactions in humans.
Exposure (AUC i /AUC) Ratios >2 for UGT Substrates:
Absence of Evidence? Figure 1 indicates that approximately three quarters of the top 200 prescribed drugs in the United States in 2002 are cleared by metabolism (www.rxlist.com). The classical view that cytochrome P450-catalyzed hydroxylations precede glucuronidation of the newly available nucleophilic oxygens holds true for many drugs. However, compounds such as zidovudine (Miners and McKenzie, 1991) are cleared primarily by direct glucuronidation without the requirement of P450 enzymes. Also, many drugs are cleared by multiple metabolism pathways of the parent compound. An example is that of olanzapine, which is metabolized by UGT1A4-catalyzed N-glucuronidation (Lin-net, 2002 ) and P450-and flavin monooxygenase-catalyzed oxidation (Ring et al., 1996) . Figure 1 shows that whereas cytochrome P450 enzymes are listed as contributors to clearance for two-thirds of drugs cleared by metabolism, compounds that are listed to undergo clearance by glucuronidation (Table 1) only make up one-seventh of that number (approximately 1 in 13 of the top 200). As previously indicated, glucuronidation may be one of several clearance mechanisms for a given drug. In any case, compared with compounds cleared by P450 enzymes, the number of drugs that appear to have glucuronidation as a clearance mechanism is small. However, they are sufficient in number for consideration of the effects (or lack thereof) of coadministration with potent in vitro inhibitors of UGT enzymes. Table 1 lists those drugs in the top 200 prescribed in 2002 that have glucuronidation as a clearance mechanism, alongside recombinant UGT enzymes known to contribute to their glucuronidation. UGT2B7 is the most commonly listed enzyme (Table 1 , 7 structurally diverse compounds of 20; 35%), followed by UGT1A4 (N-glucuronidated compounds, 20%) and UGT1A1 (15%).
For pharmacokinetic interaction studies that have been conducted for drugs cleared by glucuronidation, changes in drug exposure measured by area under the plasma concentration versus time curve (AUC) are typically less than two-fold the value observed in the absence of inhibitor (Miners and Mackenzie, 1991; Liston et al., 2001; Boase and Miners, 2002; Lin and Wong, 2002) . For example, valproate coadministration increases the plasma AUC of lorazepam by 20% (Samara et al., 1997) . One study reporting a four-fold increase in exposure of the now withdrawn drug zomepirac after concomitant administration with probenecid is an exception (Smith et al., 1985) , but probably also includes a probenecid-inhibition component of renal elimination in humans (Burckhardt and Burckhardt, 2003) . Evidence of an active transport component to drug-drug interactions mediated by P450 enzymes is an area under scrutiny (Benet et al., 2003) . For UGT substrates, our understanding of the interplay between glucuronidation and transport of glucuronides will improve with mechanistic studies (Cummings et al., 2004) to complement clinical study designs (Smith et al., 1985) .
Evidence of toxicity as a result of inhibition of UGTs is rare. An exception is lamotrigine, for which coadministration with valproic acid appears to increase the risk of rash (Garnett, 2002) . However, significant synergistic effects associated with increased efficacy also result from coadministration of valproic acid with lamotrigine (Garnett, 2002) .
Evidence of Absence I. Pharmacokinetic Principles and UGT Enzymology. Table 2 lists characteristics of drugs, which, in the presence of an inhibitor of clearance (metabolism in this case), increase the risk of a large (Ͼ5) ratio of exposure in the presence of an inhibitor compared with its absence (AUC i /AUC). When combined, these listed risk factors present the potential for the highest AUC i /AUC ratio. Therefore, high extraction drugs metabolized by a single enzyme (like terfenadine; Boxenbaum, 1999) , simultaneously presented to the liver along with an inhibitor in which the ratio of liver concentration ([I]) to potency of inhibition (K i ) is high, are at the greatest risk of having a high (Ͼ5) AUC i /AUC ratio (Table 1) , as are compounds with a low in vivo K m . Thus, the potent CYP3A inhibitor ketoconazole increases the AUC of terfenadine, which is primarily metabolized by CYP3A enzymes (Ling et al., 1995) , and has a hepatic extraction ratio of 0.9 (90% of the dose is metabolized on first pass through the liver) by approximately 35-fold (Boxenbaum, 1999) .
As indicated above, observed AUC i /AUC ratios for glucuronidated drugs coadministered with UGT inhibitors are typically less than 2. This is because drugs primarily cleared by glucuronidation generally do not have the characteristics necessary to lead to high AUC i /AUC ratios, as described below and in Table 2 . The data in Table 1 indicate that UGT substrates are often metabolized by multiple UGTs and have high K m values in vitro compared with substrates of P450 enzymes. In addition, in vitro data also suggest that inhibitor/K i ratios would also be typically low for inhibitors of UGT2B7-catalyzed AZT (3Ј-azido- 2Ј,3Ј-dideoxythymidine; zidovudine) glucuronidation (Table 3) : IC 50 values range between 186 and 4100 M for a structurally diverse set of compounds including flurbiprofen, valproic acid, and the flavonoid 3Ј,4Ј,5,5Ј,6,7-hexamethoxyflavone (HMF). The same set of compounds also indicate low potency for inhibition of UGT1A1-catalyzed estradiol 3-glucuronidation (IC 50 values Ͼ200 M), except for potent inhibition by the flavonoid hexamethoxyflavone. The potential clinical relevance (or lack thereof) of potent flavonoid inhibition of UGT1A1 will be discussed later.
As indicated in Fig. 1 , UGT2B7 is the most commonly listed UGT for biotransformation of the most prescribed drugs. Using the established relationship between IC 50 and K i (Cheng and Prusoff, 1973) , the lowest K i for this UGT2B7-catalyzed biotransformation, assuming competitive inhibition (which in many cases for UGT substrates would not be appropriate), would be approximately 100 M. Assuming noncompetitive inhibition, the lowest K i would be approximately 200 M. With notable exceptions (e.g., valproic acid), total (proteinbound and -unbound) therapeutic plasma concentrations for most drugs are below 10 M. The importance of the relationship between inhibitor concentration (I) and K i is discussed below, after consideration of the importance of K m in saturation of metabolism. Figure 2 shows the results of a simulation of the effect of drug concentration in the liver on the percentage of maximal clearance for Fig. 3 . b Boxenbaum (1999) . c See Fig. 2 and data in Table 1 .
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Inhibition of estradiol-3-glucronidation (UGT1A1) or zidovudine (AZT) glucuronidation by structurally diverse compounds in human liver microsomes
Experiments were performed according to the previously described methodology (Court et al., 2003) . HMF and valproic acid concentrations were taken to the limits of solubility. Data are means of triplicate incubations of three separate experiments for each compound. Stimulation of estradiol 3-glucuronidation increased with increasing AZT concentration to a maximal 174% of control activity at the highest AZT concentration tested (3 mM). (Fig. 2) . However, for a drug with a K m of 3 M (e.g., a P450 substrate), it can be seen that activity is reduced to 25% of the maximum at 10 M concentration. As previously indicated, since the plasma concentrations of most marketed drugs are lower than 10 M, a typical UGT substrate would therefore not be expected to saturate its own metabolism unless its hepatic concentration was in the hundreds of micromolar range. The concentrations of some UGT substrates are relatively high, e.g., valproic acid reaches plasma concentrations approaching 1 mM (Table 1) . However, the corresponding K m (e.g., for valproic acid) is in the 2 to 5 mM range (Table 1) . Although the intralumenal position of UGT enzymes differs from that of P450s, which are located on the cytoplasmic side, there are no significant differences in the pharmacokinetics (e.g., hepatic extraction ratios) of P450 and UGT substrates. Therefore, unless future evidence proves otherwise, it appears appropriate to assume that the same pharmacokinetic principles apply for both P450 and UGT substrates in vivo.
As indicated previously and in Table 2 , other influencing factors on the magnitude of drug interaction include 1) the relationship between hepatic inhibitor concentration and K i , and 2) the fraction metabolized by a single enzyme. Equation 2 was developed (Rowland and Matin, 1973) incorporating these two components for metabolized drugs to provide a sensitivity analysis of AUC i /AUC ratio to these two independent variables (Fig. 3) .
where I is inhibitor concentration, K i is a constant describing affinity of inhibitor for the enzyme, f m is the fraction of drug cleared by metabolism (as opposed to renal or biliary excretion of unchanged drug), and f m,UGT is the fraction of drug metabolized by a single UGT enzyme. When a drug's clearance is solely mediated by metabolism (f m ϭ 1) catalyzed by a single enzyme (f m,UGT ϭ 1), eq. 2 (Rowland and Matin, 1973) can be simplified to eq. 3:
Based on eq. 2 (Rowland and Matin,1973) , the predicted magnitude of interaction (AUC i /AUC) increases as the contribution of a single enzyme to the metabolism of a drug increases from 0 to 1 (Fig. 3 ). Three scenarios, in which the I/K i ratio is set at 0.1, 1, or 10, are presented in Fig. 3 . If the K i value is fixed at 10 M, the corresponding liver concentrations, according to the three fixed I/K i values, would be 1, 10, and 100 M. A value of 10 M is a conservative choice; most observed in vitro K i values for UGT inhibitors are higher than 10 M. This is exemplified by the data in Table 3 , which lists a representative group of compounds with low inhibitory potency of UGT substrates for UGT2B7-catalyzed AZT glucuronidation and UGT1A1-catalyzed estradiol 3-glucuronidation. Potent in vitro inhibition by the flavonoid hexamethoxyflavone is an exception to the otherwise generally observed small effect, and will be discussed below.
For reference purposes, an AUC i /AUC lower than 2 is considered to be within the bounds of natural interindividual variability of drug exposure in the absence of inhibitor. It can be seen from the simulation in Fig. 3 that when [I]/K i is 0.1 or 1, the predicted AUC i /AUC ratio does not rise above 2, even if a single enzyme is the only contributor to the clearance of a glucuronidated drug substrate. When [I]/K i is 10, the predicted AUC i /AUC only rises above 2 when the fraction metabolized by a single enzyme is greater than 0.6, and only rises above 3-fold when the fraction metabolized by a single enzyme rises above 0.8.
The sensitivity analysis presented in Fig. 3 is consistent with the observed pharmacokinetic findings showing low AUC i /AUC ratios for glucuronidated drugs in the presence of inhibitor, as described below. It is also consistent with the observation that, dependent on methodology, multiple recombinant UGTs contribute to the in vitro glucuronidation of aglycones such as acetaminophen (Court et al., 2001; Goosen et al., 2004c) , oxazepam (Court et al., 2002) , zidovudine and codeine (Court et al., 2003) , and CI-1027 (Bauman et al., 2004) .
AZT can be taken as a case example for assessing potential extent of drug-drug interaction. AZT is an antiviral drug with a high plasma clearance mediated by UGT2B7-catalyzed glucuronidation. With regard to potential pharmacokinetic drug-drug interactions, in the most extreme scenario (Table 2) , if AZT clearance were completely by hepatic glucuronidation, then, hepatic metabolic clearance would approach liver blood flow (20 ml/min/kg). The potential for a high AUC i /AUC ratio would therefore be high, if a situation arose where the I/K i ratio of a coadministered inhibitor was high (Fig. 3) . However, observed drug-drug interactions indicate no greater than a 100% increase in exposure in AZT in the presence of an inhibitor. This result is consistent with the pharmacokinetic principles detailed above: 70% contribution of UGT2B7 and low in vitro inhibition potency for UGT2B7-catalyzed glucuronidation of AZT in vitro (see Table 3 , and Trapnell et al., 1998) . Furthermore, for AZT, since the in vitro K m is in the 2 to 4 mM range and the therapeutic concentrations are an order of magnitude lower, assuming that in vitro K m values roughly translate to in vivo K m values and cofactor (UDP-glucuronic acid) levels are in excess, saturation of metabolism under conditions of UGT2B7 inhibition would be unlikely to occur and, thus, would not lead to a significant pharmacokinetic interaction (AUC i /AUC Ͻ2). Thus, using the data for valproic acid from Tables 1 (K i Ͼ 4100 or 2050 M, assuming noncompetitive or competitive inhibition, respectively; Cheng and Prusoff, 1973 ) and 3 (I total ϭ 805 M or I unbound ϭ 113 M) to plug into eq. 3, the greatest predicted AUC i /AUC ratio would be, in any scenario, 1.4, which slightly underestimates the observed 2-fold increase in zidovudine AUC with concomitant valproic acid administration (Lertora et al., 1994) .
II. Potent in Vitro Inhibitors of UGT Enzymes. The data presented in Table 3 and other recently published reports have indicated potent inhibition of UGTs in vitro by flavonoids such as hexamethoxyflavone (Table 3) (K i ) is varied between 0.1 (i.e., 1 M liver drug concentration and 10 M K i for the inhibitor) and 10 (i.e., 100 M liver drug concentration and 10 M K i concentration). Where the fraction metabolized is 0.5, 50% of the metabolism is catalyzed by a single UGT. The predicted AUC i /AUC ratio is only greater than 2 when the I/K i ratio is 10 and the fraction metabolized by a single UGT is greater than 0.6.
MAGNITUDE OF DRUG-DRUG INTERACTIONS FOR UGT SUBSTRATES
at ASPET Journals on June 23, 2017 dmd.aspetjournals.org silybin (Goosen et al., 2003 (Goosen et al., , 2004c : IC 50 values are in some cases reported to be less than 1 M. However, there are no clinically relevant drug-drug interactions for UGT substrates after flavonoid consumption in healthy humans.
Flavonoids are universal components of citrus fruits, consumed in significant amounts by many individuals taking drugs primarily cleared by glucuronidation. Some hydroxylated flavonoids such as chrysin (Table 4) are extensively glucuronidated in the intestine. As a consequence, bioavailability and the potential for inhibition of glucuronidation is low. Silybin (Table 4) , a major component of the herb supplement milk thistle, is a popular treatment for liver-related conditions. Some of these reports conclude that clinical relevance is likely, whereas others take the more conservative route of concluding that the clinical relevance is unknown (Goosen et al., 2004c) . However, no observed clinically relevant (relating to efficacy or toxicity) interactions relating to UGT1A1 inhibition (e.g., reduction of bilirubin glucuronidation leading to jaundice) have been reported for healthy patients taking milk thistle.
Another recent study indicated that fatty acids are potent inhibitors of human kidney cortical microsome-catalyzed 4-methyl umbelliferone glucuronidation, with a reported K i of 0.15 M (Tsoutikos et al., 2004) . The speculated clinical relevance is that during periods of renal ischemia, fatty acids may impair renal drug glucuronidation, thus compromising the protective capacity of the kidney against druginduced nephrotoxicity. However, the contribution of the kidney to systemic clearance by UGTs is thought to be low.
As with CYP3A enzymes (Ekins et al., 2003) , accumulating evidence for the allosteric behavior of UGT1A1 (Williams et al., 2002a) and UGT2B7 (Stone et al., 2003) in vitro, and of overlapping sites for substrate binding for UGT1A1 (Rios and Tephly, 2002) , suggests that extrapolation of in vitro modulation (inhibition and heterotropic activation) data to the in vivo situation for UGT substrates is becoming increasingly complex. Examples of heterotropic activation of UGT enzymes include ethinyl estradiol (Williams et al., 2002a) or AZT activation (Table 3) of estradiol 3-glucuronidation. There is an increased need to better understand the clinical relevance of in vitro UGT-ligand interactions.
III. No "Poor Metabolizer Phenotypes" due to in Vivo Inhibition of UGT Enzymes. There is a well established correlation between CYP2D6 genotype and phenotype: extensive and poor metabolizers of CYP2D6 substrates can be predicted from data on genetic polymorphisms (Sauer et al., 2003) . The phenotype of extensive CYP2D6 metabolizers can also be altered to poor metabolizer status by coadministration of potent inhibitors of the CYP2D6 enzyme. UGT1A1 is the only UGT enzyme in which there is unequivocal evidence for a genotype/phenotype correlation . The severe Crigler-Najar syndrome and the milder Gilbert's syndrome are gene-based defects in the UGT1A1 gene that result in impaired a Pooled human liver microsomes using estradiol 3-glucuronidation as a marker for UGT1A1 activity (Williams et al., 2002) unless indicated. b Recombinant UGT1A1 using HFC as substrate (Goosen et al., 2004) . Ethinylestradiol stimulation of estradiol 3-glucuronidation was maximal (180% of control activity) at the lowest tested ethinylestradiol concentration (5 M).
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Conclusions
Although speculation on the clinical relevance of in vitro observations of inhibition of glucuronidation are relatively common (e.g., Prueksaritanont et al., 2002) , appropriate mechanistic studies attempting to link in vitro inhibition with influence on AUC in humans are rare. Trapnell et al. (1998) reported reasonable correlation between in vitro inhibition of AZT glucuronidation in human liver microsomes and inhibition in humans. Recent reports on the in vitro glucuronidation of statins speculate on the potential for pharmacokinetic drugdrug interactions. However, most statins are cleared primarily by P450 enzymes or nonmetabolic routes, and, as such, the fraction metabolized by (multiple) UGTs is likely to be small, indicating potential for a small change in AUC i /AUC ratio as a result of in vivo inhibition of glucuronidation (Fig. 3) . Based on low affinity for substrate to enzyme, low affinity of inhibitor to enzyme, multiple enzyme superfamilies (e.g., both P450s and UGTs) contributing to the metabolism of the drug, as well as the potential for multiple UGTs to metabolize the drug, it is anticipated that the likelihood of pharmacokinetic drug-drug interactions is low for drugs cleared by glucuronidation. This is consistent with observations in patients, where evidence of drug-drug interactions in which AUC i /AUC ratios are Ͼ2 or there are clinically relevant drug-drug interactions are rare. It is important that these considerations be taken into account when speculating on the in vivo relevance of observed in vitro inhibition for drugs partly or primarily cleared by glucuronidation in humans.
